A few days after launching TreatmentMAP, Woodlands-based MolecularHealth, a laboratory committed to translating genetic language into actionable information, announced cancer researcher Waun Ki Hong as the newest member of its advisory board.
One of the nation’s leaders in medical oncology and currently serving as the head of the cancer medicine division at the University of Texas MD Anderson Cancer Center, Dr. Hong brings his 36 years of experience in translational and clinical research and expertise on the treatment of head, neck and lung cancer.
During his career, Dr. Hong has contributed to several major advancements in medicine, such as organ preservation, with the development of treatment approaches that serve as alternatives to radical surgery; chemoprevention, of which he is one of the founders; genetic alterations in former smokers; personalized cancer therapy, with the development of molecular targeted therapies for lung cancer; and genetic risk models.
Dr. Hong is also an American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, professor of thoracic/head and neck medical oncology, and former president of the of the American Association for Cancer Research. Last year, he was named member of the Institute of Medicine of the National Academies.
Dr. Hong sees MolecularHealth as a “unique company,” which has “the capability to deliver patients’ genomic profiling reports to practicing oncologists quickly and accurately.” While serving at the Woodlands company, he will continue his work on treating patients with effectively targeted therapies by identifying specific gene mutations in patient tumor tissue that drive cancer cells to grow, and can simultaneously be hijacked by a specific matched targeted agent.
CEO of MolecularHealth, Lloyd Everson, recognizes Dr. Hong’s leadership in personalized medicine, adding that the company is “very pleased to be working with him.”